See the Future of Tissue Imaging

Introducing the Hyperion™ Imaging System

Watch Chris Linthwaite, President and CEO of Fluidigm, introduce the Hyperion™ Imaging System at the Future of Imaging announcement event held on October 24, 2017, in Toronto, Canada.

During this 90-minute program you will also hear three leading researchers share their insights and experiences with this revolutionary new approach to tissue imaging in the context of their own translational research programs.

Previously viewed live by researchers from around the world, this exciting program is now available to view on-demand.

The Hyperion Imaging System significantly expands the number of protein biomarkers that can be simultaneously detected from tissues and tumors as compared to results from standard fluorescent immunohistochemistry (IHC) methods. With the potential to revolutionize disease research and change the way diseases are treated and ultimately cured in the future, this new approach provides researchers with an unprecedented view of complex cellular phenotypes and their relationships in the context of the tissue microenvironment.


A New View:   
Empowering a Revolution in Tissue Imaging
Chris Linthwaite
President and CEO

Uncovering Cellular Social Networks: 
Analysis of Tissue Ecosystems in Health 
and Disease by Imaging Mass Cytometry
Bernd Bodenmiller, PhD
Assistant Professor
Institute of Molecular Life Sciences
University of Zurich

Empowering Drug Discovery and Development:
Incorporating Imaging Mass Cytometry into a Multi-Platform Tissue Testing Workflow
Matt Silver, PhD
Principal Scientist
Global Clinical Biomarkers and Companion Diagnostics
EMD Serono

Advancing Translational and Clinical Research:
Imaging Mass Cytometry to Characterize the Tumor Immune Microenvironment   
Akil Merchant, MD
Assistant Professor of Medicine
Keck School of Medicine
University of Southern California

Learn more about how the Hyperion™ Imaging System significantly expands the number of protein markers that can be simultaneously detected in tumors and tissues by Imaging Mass Cytometry™.